TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01989689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50mg twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50mg twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02275390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Psycho-education (or SPBB: self-learning program)
Description: The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Psychiatric Outpatient Care
Description: These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Psychiatric Outpatient Care
Description: These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
Study: NCT03362788

Intervention type: DRUG
Intervention: VKA
Description: VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.

Intervention type: DRUG
Intervention: NOAC
Description: NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone
Study: NCT01989689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02873559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Testosterone supplemented in 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: Testosterone supplemented in 5 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle training
Description: Progressive muscle training during 4 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle training
Description: Progressive muscle training during 4 months
Study: NCT00391170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dexamethasone
Description: dexamethasone 0.01%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02878616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Description: LFG316 single dose
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone
Study: NCT00492986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Study: NCT01884493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real iTBS
Description: Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
Study: NCT02766283

Intervention type: DRUG
Intervention: iodinated contrast agents
Description: Intravascular application
Study: NCT03624907

Intervention type: RADIATION
Group type: OTHER
Intervention: Daily Stereotactic Body Radiotherapy
Description: After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.

Intervention type: RADIATION
Group type: OTHER
Intervention: Non-Daily Stereotactic Body Radiotherapy
Description: After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
Study: NCT04167592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzydamine Hydrochloride 0.15% Oral Rinse
Description: Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
Study: NCT00041132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 on day 1 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
Study: NCT02878616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG single dose
Study: NCT00041132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 12 g/m\^2 over days 3-4 of cycles 2,4,6,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
Study: NCT01291212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone and FSHr-LHr
Description: 75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
Study: NCT01884493

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: real iTBS
Description: Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham iTBS
Description: The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
Study: NCT04185974

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C12 re-irradiation
Description: 51 Gy(RBE) or 54 Gy
Study: NCT00041132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 170 mg over days 3-5 of cycles 2,4,6,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7
Study: NCT01016470

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VIUSID/ALZER
Description: VIUSID/ALZER, 3 per day, oral, one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
Study: NCT03200912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Picato®)
Description: Brand product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Ingenol Mebutate
Description: Generic formulated to have the same therapeutic effect of the brand

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
Study: NCT03904264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver in the canal (RIC) hearing aids
Description: The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
Study: NCT03847298

Intervention type: OTHER
Intervention: Physical activity and physical fitness assessment
Description: Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.

Intervention type: OTHER
Intervention: Physical activity and physical fitness assessment
Description: Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
Study: NCT04185974

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon re-irradiation
Description: 54 Gy(RBE) or 60 Gy
Study: NCT04143165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural block with lidocaine and triamcinilone
Description: caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
Study: NCT02827383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair Climbing Frequency
Description: Includes 1 sedentary day prior to completing crossover phases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair Climbing Frequency
Description: Includes 1 sedentary day prior to completing crossover phases.
Study: NCT03843944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
Study: NCT02291393

Intervention type: DEVICE
Group type: OTHER
Intervention: 80 lead ECG

Intervention type: DEVICE
Group type: OTHER
Intervention: 80 lead ECG
Study: NCT04128397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional stimulation site continuous theta burst stimulation (cTBS)
Description: before cTBS treatment, MRI was used to confirm the stimulation site
Study: NCT01291212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone and FSHr alone
Description: FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
Study: NCT04128397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: precise stimulation site cTBS
Description: before cTBS treatment, rs-fMRI was used to confirm the stimulation site
Study: NCT01921218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitor therapy
Description: Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
Study: NCT03593018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Azacitidine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: Romidepsin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine injection
Study: NCT03883308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain cognitive training
Description: The cognitive exercises are designed to train executive functions and memory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cross-word puzzle training
Description: The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
Study: NCT01061476

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment sleep study (Provent™ device used)
Description: The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline sleep study (No device)
Description: The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
Study: NCT01921218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
Study: NCT00693017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: 50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)
Study: NCT02764528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic
Description: Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic + home
Description: Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
Study: NCT00849485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 750 mg Tablet
Study: NCT02764528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic + home + handwashing device
Description: Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
Study: NCT00849485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 750 mg Tablet
Study: NCT03177941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eviderma Smart Phone Teledermatology Application (Eviderma)
Description: First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eviderma Smart Phone Teledermatology Application (Eviderma)
Description: First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
Study: NCT02436694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic ropivacaíne
Description: Femoral and sciatic nerve block with ropivacaíne

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetic ropivacaíne
Description: Femoral and sciatic nerve block with ropivacaíne

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural Dexamethasone
Description: Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
Study: NCT01061476

Intervention type: OTHER
Group type: OTHER
Intervention: Physiology sleep study (Provent™ on/off)
Description: During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
Study: NCT03947944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMILE using manifest refraction planning
Description: The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
Study: NCT02128815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
Study: NCT04385641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell infusion for Dose-finding (Group A)
Description: Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell infusion for Extended research (Group B)
Description: Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
Study: NCT03989427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brushing first and Flossing later (BF)
Description: Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.